Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Piritrexim. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR known ✓ | P00374 | 4/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piritrexim SCHEMBL29365922 | 0.89 | DHFR (1.00) | DHFR | |
| Piritrexim SCHEMBL29462191 | 0.89 | DHFR (1.00) | DHFR | |
| Piritrexim SCHEMBL8124 | 0.89 | DHFR (1.00) | DHFR | |
| Piritrexim SCHEMBL9687400 | 0.88 | DHFR (0.98) | DHFR | |
| SCHEMBL10644399 | 0.80 | DHFR (0.78) | DHFR | |
| SCHEMBL10644572 | 0.80 | DHFR (0.78) | DHFR | |
| Piritrexim SCHEMBL28201443 | 0.79 | DHFR (0.80) | DHFR | |
| Trimetrexate SCHEMBL6013903 | 0.76 | DHFR (0.70) | DHFR | |
| SCHEMBL11006578 | 0.73 | DHFR (0.71) | DHFR | |
| SCHEMBL10465187 | 0.71 | DHFR (0.67) | DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 536 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200253994-A1 | PYRIMIDINE DERIVATIVE CONTAINING COMPOSITIONS | CHEMISTRYRX (US) | 2020-08-13 | — | — | US | claimed |
| US-20100323979-A1 | METHODS AND COMPOSITIONS FOR INHIBITING PROLIFERATION OF ANEUPLOID CELLS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2010-12-23 | — | — | US | claimed |
| WO-2010147663-A1 | METHODS AND COMPOSITIONS FOR INHIBITING PROLIFERATION OF ANEUPLOID CELLS | MASSECHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2010-12-23 | — | — | WO | claimed |
| US-7071158-B2 | Antioxidant enhancement of therapy for hyperproliferative conditions | ATHEROGENICS, INC. (US) | 2006-07-04 | — | — | US | claimed |
| US-20010049349-A1 | Antioxidant enhancement of therapy for hyperproliferative conditions | CRABTREE ACQUISITION CO, LLC | 2001-12-06 | — | — | US | claimed |
| CN-1261803-A | Antioxidant enhancement of therapy for hyperproliferative conditions | ATHEROGENICS INC (US) | 2000-08-02 | — | — | CN | claimed |
| EP-4724485-A1 | BACKPACKED-ANTIBODY CONSTRUCTS AND THEIR USES | Universidad del País Vasco/Euskal Herriko Unibertsitatea (ES) | 2026-04-15 | — | — | EP | disclosed |
| US-20260034071-A1 | HIGH-PURITY PEG LIPIDS AND USES THEREOF | MODERNATX, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4541381-B1 | STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS | ADVANCED ACCELERATOR APPLICATIONS S A (FR) | 2026-02-04 | — | — | EP | disclosed |
| US-20260007758-A1 | SOMATOSTATIN SUBTYPE-2 RECEPTOR (SST2R) NON-PEPTIDE DRUG CONJUGATES AND USES THEREOF | CRINETICS PHARMACEUTICALS INC (US) | 2026-01-08 | — | — | US | disclosed |
| EP-4545100-B1 | STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS | ADVANCED ACCELERATOR APPLICATIONS S A (FR) | 2025-12-10 | — | — | EP | disclosed |
| EP-4545101-B1 | STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS | ADVANCED ACCELERATOR APPLICATIONS S A (FR) | 2025-12-10 | — | — | EP | disclosed |
| EP-4541380-B1 | STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS | ADVANCED ACCELERATOR APPLICATIONS S A (FR) | 2025-12-10 | — | — | EP | disclosed |
| EP-0909183-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | Neuromedica, Inc. (US) | 1999-04-21 | — | — | EP | disclosed |
| WO-1999001118-A2 | ANTIOXIDANT ENHANCEMENT OF THERAPY FOR HYPERPROLIFERATIVE CONDITIONS | ATHEROGENICS, INC. (US) | 1999-01-14 | — | — | WO | disclosed |
| US-5795909-A | ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS | NEUROMEDICA, INC. (US) | 1998-08-18 | — | — | US | disclosed |
| WO-1997044063-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | NEUROMEDICA, INC. (US) | 1997-11-27 | — | — | WO | disclosed |
| EP-0279565-B1 | MEDICAMENTS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-01-02 | — | — | EP | disclosed |
| US-4818759-A | RHEUMATOID ARTHRITIS | BURROUGHS WELLCOME CO., A CORP. OF NORTH CAROLINA | 1989-04-04 | — | — | US | disclosed |
| EP-0279565-A1 | Medicaments for the treatment of rheumatoid arthritis | THE WELLCOME FOUNDATION LIMITED (GB) | 1988-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034071-A1 | HIGH-PURITY PEG LIPIDS AND USES THEREOF | LNPEP, AUP1, PLTP | DHFR 3585/4885 |
| US-20260007758-A1 | SOMATOSTATIN SUBTYPE-2 RECEPTOR (SST2R) NON-PEPTIDE DRUG CONJUGATES AND USES THEREOF | SSTR4, SSTR1, SSTR3 | DHFR 2643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.